|Bid||761.30 x 0|
|Ask||761.30 x 0|
|Day's range||732.00 - 762.50|
|52-week range||475.45 - 834.50|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||35.41|
|Forward dividend & yield||10.40 (1.37%)|
|Ex-dividend date||25 Mar 2022|
|1y target est||784.25|
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate